BCG and protection against inflammatory and auto-immune diseases

References

• Calmette A, Guérin C. Sur quelques propriétés du bacilli tuberculeux d’origine bovine, cultivé sur la bile de boeuf glycérinée. Compt Rend Acad Sci. 1909;149:716–718.
   Google Scholar
• Calmette A, Guérin C, Nègre L, et al. Prémunition des nouveaux-nés contre la tuberculose par le vaccin BCG (1921 à 1926). Ann Inst Pasteur. 1926;40:89–133.
   Google Scholar
• Monteiro-Maia R, De Pinho T. Oral bacillus Calmette-Guérin vaccine against tuberculosis: why not? Mem Inst Oswaldo Cruz. 2014;109:838–845.
   PubMed Web of Science ®Google Scholar
• World Health Organization. BCG vaccine. WHO position paper. Wkly Epidemiol Rec. 2004;79:27–38.
   PubMedGoogle Scholar
• Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analysis of the published literature. Pediatrics. 1995;96:29–35.
   PubMed Web of Science ®Google Scholar
• Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. Jama. 1994;271:698–702.
   PubMed Web of Science ®Google Scholar
• Parkash O. How to avoid the impact of environmental mycobacteria towards the efficacy of BCG vaccination against tuberculosis? Int J Mycobacteriol. 2014;3:1–4.
   PubMedGoogle Scholar
• Soysal A, Millington KA, Bakir M, et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet. 2005;366:1443–1451.
   PubMed Web of Science ®Google Scholar
• Mascart F, Locht C. Integrating knowledge of Mycobacterium tuberculosis pathogenesis for the design of better vaccines. Expert Rev Vaccines. 2015;14:1573–1585.
   PubMed Web of Science ®Google Scholar
• Lewis KN, Liao R, Guinn KM, et al. Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guérin attenuation. J Infect Dis. 2003;187:117–123.
   PubMed Web of Science ®Google Scholar
• Van Der Wel N, Hava D, Houben D, et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid. Cells Cell. 2007;129:1287–1298.
   PubMed Web of Science ®Google Scholar
• Pym AS, Brodin P, Majlessi L, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med. 2003;9:533–539.
   PubMed Web of Science ®Google Scholar
• Brosch R, Gordon SV, Garnier T, et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA. 2007;104:5596–5601.
   PubMed Web of Science ®Google Scholar
• Magdalena J, Supply P, Locht C. Specific differentiation between Mycobacterium bovis BC and virulent strains or the Mycobacterium tuberculosis complex. J Clin Microbiol. 1998;36:2471–2476.
   PubMed Web of Science ®Google Scholar
• Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science. 1999;284:1520–1523.
   PubMed Web of Science ®Google Scholar
• Stanley SJ, Howland C, Stone MM, et al. BCG vaccination of children against leprosy in Uganda: final results. J Hyg Camb. 1981;87:233–248.
   PubMedGoogle Scholar
• Orege PA, Fine PE, Lucas SB, et al. Case-control study of BCG vaccination as a risk factor for leprosy and tuberculosis in western Kenya. Int J Lepr Other Mycobact Dis. 1993;61:542–549.
   PubMedGoogle Scholar
• Pönnighaus JM, Fine PE, Sterne JA, et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet. 1992;339:636–639.
   PubMed Web of Science ®Google Scholar
• Setia MS, Steinmaus C, Ho CS, et al. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis. 2006;6:162–170.
   PubMed Web of Science ®Google Scholar
• Rodrigues LC, Pereira SM, Cunha SS, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet. 2005;366:1290–1295.
   PubMed Web of Science ®Google Scholar
• Cunha SS, Alexander N, Barreto ML, et al. BCG revaccination does not protect against leprosy in the Brazilian Amazon: a cluster randomised trial. Plos Negl Trop Dis. 2008;13:e167.
   Web of Science ®Google Scholar
• MacCallum P, Tolhurst JC, Buckle G, et al. A new mycobacterial infection in man. J Pathol Bacteriol. 1948;60:93–122.
   PubMedGoogle Scholar
• The Uganda Buruli Group. B.C.G. Vaccination against Mycobacterium ulcerans infection (Buruli ulcer). Lancet. 1969;1:111–115.
   PubMed Web of Science ®Google Scholar
• Portaels F, Aguiar J, Debacker M, et al. Prophylactic effect of Mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli ulcer). Clin Diag Lab Immunol. 2002;9:1389–1391.
   PubMedGoogle Scholar
• Raghunathan PL, Whitney EA, Asamoa K, et al. Risk factors for Buruli ulcer disease (Mycobacterium ulcerans infection): results from a case-control study in Ghana. Clin Infect Dis. 2005;40:1445–1453.
   PubMed Web of Science ®Google Scholar
• Nackers F, Dramaix M, Johnson RC, et al. BCG vaccine effectiveness against Buruli ulcer: a case-control study in Benin. Am J Trop Med Hyg. 2006;75:768–774.
   PubMed Web of Science ®Google Scholar
• Phillips RO, Phanzu DM, Beissner M, et al. Effectiveness of routine BCG vaccination on Buruli ulcer disease: a case-control study in the Democratic Republic of Congo, Ghana and Togo. Plos Negl Trop Dis. 2015;9:e3457.
   PubMed Web of Science ®Google Scholar
• Converse PJ, Almeida DV, Nuermberger EL, et al. BCG-mediated protection against Mycobacterium ulcerans infection in the mouse. Plos Negl Trop Dis. 2011;5:e985.
   PubMed Web of Science ®Google Scholar
• Pearl R. Cancer and tuberculosis. Am J Hyg. 1929;9:97–159.
   Google Scholar
• Old LJ, Clarke DA, Benacerraf B. The effect of bacillus Calmette-Guérin infection on transplanted tumors in mice. Nature. 1959;184:291–292.
   PubMed Web of Science ®Google Scholar
• Silverstein MJ, DeKernion J, Morton DL. Malignant melanoma metastatic to the bladder. Regression following intratumor injection of BCG vaccine. Jama. 1974;229:688.
   PubMed Web of Science ®Google Scholar
• Herr HW, Morales A. History of bacillus Calmette-Guérin and bladder cancer: an immunotherapy success story. J Urol. 2008;179:53–56.
   PubMed Web of Science ®Google Scholar
• Kuroda K, Brown EJ, Telle WB, et al. Characterization of the internalization of bacillus Calmette-Guérin by human bladder tumor cells. J Clin Invest. 1993;91:69–76.
   PubMed Web of Science ®Google Scholar
• Ludwig AT, Moore JM, Luo Y, et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity. Cancer Res. 2004;64:3386–3390.
   PubMed Web of Science ®Google Scholar
• Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival; follow up study in Guinea-Bissau, West Africa. Bmj. 2000;321:1–8.
   PubMed Web of Science ®Google Scholar
• Naeslund C. Expérience de vaccination par le BCG dans la province du Norrbotten (Suède). Rev Tuberc. 1931;12:617–636.
   Google Scholar
• Beiring-Sorensen S, Aaby P, Napirna BM, et al. Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guérin vaccination at first health center contact. Pediatr Infect Dis J. 2012;31:306–308.
   PubMed Web of Science ®Google Scholar
• Hollm-Delgado MG, Stuart EA, Black RE. Acute lower respiratory infection among bacille Calmette-Guérin (BCG)-vaccinated children. Pediatrics. 2014;133:e73–e81.
   PubMed Web of Science ®Google Scholar
• Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA. 2012;109:17537–17542.
   PubMed Web of Science ®Google Scholar
• Arts RJ, Carvalho A, LaRocca C, et al. Immunometabolic pathways in BCG-induced trained immunity. Cell Rep. 2016;17:2562–2571.
   PubMed Web of Science ®Google Scholar
• Johansson SG, Hourihane JO, Bousquet J, et al. EAACI (the European Academy of Allergology and Clinical Immunology) nomenclature task force – a revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy. 2001;56:813–824.
   PubMed Web of Science ®Google Scholar
• Akdis M. New treatments for allergen immunotherapy. World Allergy Org J. 2014;7:23.
   PubMedGoogle Scholar
• Bantz SK, Zhu Z, Zheng T. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. J Clin Cell Immunol. 2014;5:2.
   Google Scholar
• Gould HJ, Ramadani F. IgE responses in mouse and man and the persistence of IgE memory. Trends Immunol. 2015;36:40–48.
   PubMed Web of Science ®Google Scholar
• Brooks C, Pearce N, Douwes J. The hygiene hypothesis in allergy and asthma: an update. Curr Opin Allergy Clin Immunol. 2013;13:70–77.
   PubMed Web of Science ®Google Scholar
• Braun-Fahrländer C, Gassner M, Grize L, et al. Prevalence of hay fever and allergic sensitization in farmer’s children and their peers living in the same rural community. Clin Exp Allergy. 1999;29:28–34.
   PubMed Web of Science ®Google Scholar
• Hogg C. T-helper polarization in atopic disease – how early does it occur? Clin Exp Allergy. 1997;27:1237–1239.
   PubMed Web of Science ®Google Scholar
• Rook GAW, Hamelmann E, Brunet LR. Mycobacteria and allergies. Immunobiology. 2007;212:461–473.
   PubMed Web of Science ®Google Scholar
• Erb KJ, Holloway JW, Sobeck A, et al. Infection of mice with Mycobacterium bovis bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. J Exp Med. 1998;187:561–569.
   PubMed Web of Science ®Google Scholar
• Hopfenspriger MT, Agrawal DK. Airway hyperresponsiveness, late allergic response, and eosinophilia are reversed with mycobacterial antigens in ovalbumin-presensitized mice. J Immunol. 2002;168:2516–2522.
   PubMed Web of Science ®Google Scholar
• Barlan I, Bahceciler NN, Akdis M, et al. Bacillus Calmette-Guérin, Mycobacterium bovis, as an immunomodulator in atopic diseases. Immunol Allergy Clin North Am. 2006;26:365–377.
   PubMed Web of Science ®Google Scholar
• Herz U, Gerhold K, Grüber C, et al. BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model. J Allergy Clin Immunol. 1998;102:867–874.
   PubMed Web of Science ®Google Scholar
• Scanga CB, Le Gros G. Development of an asthma vaccine: research into BCG. Drugs. 2000;59:1217–1221.
   PubMed Web of Science ®Google Scholar
• Zuany-Amorim C, Sawicka E, Manlius C, et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med. 2002;8:625–629.
   PubMed Web of Science ®Google Scholar
• Akdis M, Verhagen J, Taylor A, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med. 2004;199:1567–1575.
   PubMed Web of Science ®Google Scholar
• Ahrens B, Gruber C, Rha RD, et al. BCG priming of dendritic cells enhances T regulatory and Th1 function and suppresses allergen-induced Th2 function in vitro and in vivo. Int Arch Allergy Immunol. 2009;150:210–220.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Kim HJ, Kang MJ, et al. Bacillus Calmette-Guérin suppresses asthmatic responses via CD4(+)CD25(+) regulatory T cells and dendritic cells. Allergy Asthma Immunol Res. 2014;6:201–207.
   PubMed Web of Science ®Google Scholar
• Qu SY, Ou-Yang HF, He YL, et al. Der p2 recombinant bacille Calmette-Guerin priming of bone marrow-derived dendritic cells suppresses Der p2-induced T helper17 function in a mouse model of asthma. Respirology. 2014;19:122–131.
   PubMed Web of Science ®Google Scholar
• Okamura HH, Tsutsi T, Komatsu M, et al. Cloning of a new cytokine that induces IFN gamma production by T cells. Nature. 1995;378:88–91.
   PubMed Web of Science ®Google Scholar
• Wawrocki S, Druszczynska M, Kowalewicz-Kulbat M, et al. Interleukin 18 (IL-18) as a target for immune intervention. Acta Biochim Pol. 2016;63:59–63.
   PubMed Web of Science ®Google Scholar
• Ming-Hui X, Feng-Lai Y, Shu-Jing W, et al. Association of interleukin-18 and asthma. Inflammation. 2017;40:324–327.
   PubMed Web of Science ®Google Scholar
• Kowalewicz-Kulbat M, Pestel J, Biet F, et al. Mycobacterium bovis BCG Mycobacteria – new application. Pol J Microb. 2006;15:13–17.
   Google Scholar
• Biet F, Kremer L, Wolowczuk I, et al. Mycobacterium bovis BCG producing interleukin-18 increases antigen-specific gamma interferon production in mice. Infect Immun. 2002;60:6549–6557.
   Web of Science ®Google Scholar
• Biet F, Duez C, Kremer L, et al. Recombinant Mycobacterium bovis BCG producing IL-18 reduces IL-5 production and bronchoalveolar eosinophilia induced by an allergic reaction. Allergy. 2005;60:1065–1072.
   PubMed Web of Science ®Google Scholar
• Luo Y, Yamada H, Chen X, et al. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin Exp Immunol. 2004;137:24–34.
   PubMed Web of Science ®Google Scholar
• Szpakowski P, Biet F, Locht C, et al. Dendritic cell activity driven by recombinant Mycobacterium bovis BCG producing human IL-18, in healthy BCG vaccinated adults. J Immunol Res. 2015;2015:359153.
   PubMed Web of Science ®Google Scholar
• Shirakawa T, Enomoto T, Shimazu S, et al. The inverse association between tuberculin responses and atopic disorder. Science. 1999;275:77–79.
   Web of Science ®Google Scholar
• Aaby P, Shaheen SO, Heyes CB, et al. Early BCG vaccination and reduction in atopy in Guinea-Bissau. Clin Exp Allergy. 2000;30:644–650.
   PubMed Web of Science ®Google Scholar
• Marks GB, Ng K, Zhou J, et al. The effect of neonatal BCG vaccination on atopy and asthma at age 7 to 14 years: an historical cohort study in a community with a very low prevalence of tuberculosis infection and a high prevalence of atopic disease. J Allergy Clin Immunol. 2003;111:541–549.
   PubMed Web of Science ®Google Scholar
• Grüber C, Kulig M, Bergmann R. Delayed hypersensitivity to tuberculin total immunoglobulin E, specific sensitization, and atopic manifestation in longitudinally followed early bacille-Calmette-Guérin-vaccinated and nonvaccinated children. Pediatrics. 2001;107:E36.
   PubMed Web of Science ®Google Scholar
• Omenaas E, Jentoft HF, Vollmer WM, et al. Absence of relationship between tuberculin reactivity and atopy in BCG vaccinated young adults. Thorax. 2000;55:454–458.
   PubMed Web of Science ®Google Scholar
• Strannegard I, Larsson L, Wennergren G, et al. Prevalence of allergy in children in relation to prior BCG vaccination and infection with atypical mycobacteria. Allergy. 1998;53:249–254.
   PubMed Web of Science ®Google Scholar
• Alm J, Lilja G, Pershagen G, et al. Early BCG vaccination and the development of atopy. Lancet. 1997;350:400–403.
   PubMed Web of Science ®Google Scholar
• Linehan MF, Nurmatov U, Frank TL, et al. Does BCG vaccination protect against childhood asthma? Final results from the Manchester Community Asthma Study retrospective cohort study and updated systematic review and meta-analysis. J Allergy Clin Immunol. 2014;133:688–695.
   PubMed Web of Science ®Google Scholar
• Andersen E, Isager H, Hyllested K. Risk factors in multiple sclerosis tuberculin reactivity, age at measles infection, tonsillectomy and appendectomy. Acta Neurol Scandinav. 1981;63:131–135.
   PubMed Web of Science ®Google Scholar
• Ristori G, Buzzi M, Sabatini U, et al. Use of bacille Calmette-Guérin (BCG) in multiple sclerosis. Neurology. 1999;53:1588–1589.
   PubMed Web of Science ®Google Scholar
• Paolillo A, Buzzi MG, Giugni E, et al. The effect of bacille Calmette-Guérin on the evolution of new enhancing lesions to hypointense T1 lesions in relapsing remitting MS. J Neurol. 2003;250:247–248.
   PubMed Web of Science ®Google Scholar
• Ristori G, Romano S, Cannoni S, et al. Effects of bacille Calmette-Guérin after the first demyelinating event in the CNS. Neurology. 2014;82:41–48.
   PubMed Web of Science ®Google Scholar
• Sewell DL, Reinke EK, Co DO, et al. Infection with Mycobacterium bovis BCG diverts traffic of myelin oligodendroglial glycoprotein autoantigen-specific T cells away from the central nervous system and ameliorates experimental autoimmune encephalomyelitis. Clin Diag Lab Immunol. 2003;10:564–572.
   PubMedGoogle Scholar
• Dalton DK, Haynes L, Chu CQ, et al. Interferon gamma eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J Exp Med. 2000;192:117–122.
   PubMed Web of Science ®Google Scholar
• O’Connor RA, Wittmer S, Dalton DK. Infection-induced apoptosis deletes bystander CD4+ T cells: a mechanism for suppression of autoimmunity during BCG infection. J Autoimmun. 2005;24:93–100.
   PubMed Web of Science ®Google Scholar
• Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123–1132.
   PubMed Web of Science ®Google Scholar
• Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 2006;177:566–573.
   PubMed Web of Science ®Google Scholar
• Lee JE, Reinke EK, Zozulya AL, et al. Mycobacterium bovis bacille Calmette-Guérin infection in the CNS suppresses experimental autoimmune encephalomyelitis and Th17 responses in an IFN-γ-independent manner. J Immunol. 2008;181:6201–6212.
   PubMed Web of Science ®Google Scholar
• Lampropoulou V, Hoehlig K, Roch T, et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol. 2008;180:4763–4773.
   PubMed Web of Science ®Google Scholar
• Patterson C, Guariguata L, Dahlquist G, et al. Diabetes in the young – a global view and worldwide estimates of numbers of children with type 1 diabetes. Diabetes Res Clin Pract. 2014;103:161–175.
   PubMed Web of Science ®Google Scholar
• Cabrera SM, Rigby MR, Mirmira RG. Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. Curr Mol Med. 2012;12:1261–1272.
   PubMed Web of Science ®Google Scholar
• Stankov K, Benc D, Draskovic D. Genetic and epigenetic factors in etiology of diabetes mellitus type 1. Pediatrics. 2013;132:1112–1122.
   PubMed Web of Science ®Google Scholar
• Kleinnijenhuis J, Quintin J, Preijers F, et al. Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J Innate Immun. 2014;6:152–158.
   PubMed Web of Science ®Google Scholar
• Sadelain MW, Quin HY, Lauzon J, et al. Prevention of type 1 diabetes in NOD mice by adjuvant immunotherapy. Diabetes. 1990;39:583–589.
   PubMed Web of Science ®Google Scholar
• Shehadeh N, Calcinaro F, Bradley BJ, et al. Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet. 1994;343:706–707. Erratum in: Lancet. 2006;367:1240. Bruchlim, I [corrected to Bruchim, I].
   PubMed Web of Science ®Google Scholar
• Allen HF, Klingensmith GJ, Jensen P, et al. Effect of bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes: a randomized clinical study. Diabetes Care. 1999;22:1703–1707.
   PubMed Web of Science ®Google Scholar
• Khan M, Aydin M. Effect of BCG vaccine in the prevention of type 1 diabetes mellitus. Contemp J Med. 2012;2:1–8.
   Google Scholar
• Faustman DL, Wang L, Okubo Y, et al. Proof-of-concept, randomized, controlled clinical trial of bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. Plos One. 2012;7:e41756.
   PubMed Web of Science ®Google Scholar
• Elliott JF, Marlin KL, Couch RM. Effect of bacille Calmette-Guérin vaccination on C-peptide secretion in children newly diagnosed with IDDM. Diabetes Care. 1998;21:1691–1693.
   PubMed Web of Science ®Google Scholar
• Sanjeevi CB, Das AK, Shtauvere-Brameus A. BCG vaccination and GAD65 and IA-2 autoantibodies in autoimmune diabetes in southern India. Ann N Y Acad Sci. 2002;958:293–296.
   PubMed Web of Science ®Google Scholar
• EURODIAB Substudy 2 Study Group. Infections and vaccinations as risk factors for childhood type I (insulin-dependent) diabetes mellitus: a multicentre case-control investigation. Diabetologia. 2000;43:47–53.
   Web of Science ®Google Scholar
• Parent ME, Siemiatycki J, Menziez R, et al. Bacille Calmette-Guerin vaccination and incidence of IDDM in Montreal, Canada. Diabetes Care. 1997;20:767–772.
   PubMed Web of Science ®Google Scholar
• Dahlquist G, Gothefors L. The cumulative incidence of childhood diabetes mellitus in Sweden unaffected by BCG-vaccination (Letter). Diabetologia. 1995;38:873–874.
   PubMed Web of Science ®Google Scholar
• Huppmann M, Baumgarten A, Ziegler AG, et al. Neonatal bacille Calmette-Guerin vaccination and type 1 diabetes. Diabetes Care. 2005;28:1204–1206.
   PubMed Web of Science ®Google Scholar
• Rousseau MC, El-Zein M, Conus F, et al. Bacillus Calmette-Guérin (BCG) vaccination in infancy and risk of childhood diabetes. Paediatr Perinat Epidemiol. 2016;30:141–148.
   PubMed Web of Science ®Google Scholar
• Kodama S, Kühtreiber W, Fujimura S, et al. Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science. 2003;302:1223–1227.
   PubMed Web of Science ®Google Scholar
• Makino S, Kunimoto M, Muraoka Y, et al. Breeding of a non-obese, diabetic strain of mice. Exp Anim. 1980;29:1–13.
   PubMedGoogle Scholar
• Yagi H, Matsumoto M, Suzuki S, et al. Possible mechanism of the preventive effect of BCG against diabetes mellitus in NOD mouse. Cell Immunol. 1991;138:130–141.
   PubMed Web of Science ®Google Scholar
• Da Rosa LC, Chiuso-Minicucci F, Zorzella-Pezavento SF, et al. Bacille Calmette-Guerin/DNAhsp65 prime-boost is protective against diabetes in non-obese diabetic mice but not in the streptozotocin model of type 1 diabetes. Clin Exp Immunol. 2013;173:430–437.
   PubMed Web of Science ®Google Scholar
• Huda MN, Lewis Z, Kalanetra KM, et al. Stool microbiota and vaccine responses in infants. Pediatrics. 2014;134:e362–e372.
   PubMed Web of Science ®Google Scholar